Pathology: mBC - TNBC - L1 - PDL1 positive;
| mBC - TNBC - L1 - PDL1 positive | |||||
| IMpassion-130 (PDL1>1%), 2018 | IMpassion-131 (PD-L1 > 1%), 2020 | KEYNOTE-355 (CPS>1), 2020 | KEYNOTE-355 (CPS>10), 2020 | ||
| pembrolizumab plus SoC | 2 | T1 | T1 | ||
| atezolizumab plus paclitaxel | 1 | T1 | |||
| atezolizumab plus nab-paclitaxel | 1 | T1 | |||
| placebo plus SoC | 0 | T0 | T0 | ||
| Standard of Care (SoC) | 0 | T0 | T0 | ||